TY - JOUR
T1 - Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase
AU - Drabkin, Max
AU - Yogev, Yuval
AU - Zeller, Lior
AU - Zarivach, Raz
AU - Zalk, Ran
AU - Halperin, Daniel
AU - Wormser, Ohad
AU - Gurevich, Evgenia
AU - Landau, Daniel
AU - Kadir, Rotem
AU - Perez, Yonatan
AU - Birk, Ohad S.
N1 - Publisher Copyright:
Copyright: © 2019, American Society for Clinical Investigation.
PY - 2019/12/2
Y1 - 2019/12/2
N2 - Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid. Although molecular pathways of this underexcretion have been elucidated, its etiology remains mostly unknown. We demonstrate that gout can be caused by a mutation in LDHD within the putative catalytic site of the encoded d-lactate dehydrogenase, resulting in augmented blood levels of d-lactate, a stereoisomer of l-lactate, which is normally present in human blood in miniscule amounts. Consequent excessive renal secretion of d-lactate in exchange for uric acid reabsorption culminated in hyperuricemia and gout. We showed that LDHD expression is enriched in tissues with a high metabolic rate and abundant mitochondria and that d-lactate dehydrogenase resides in the mitochondria of cells overexpressing the human LDHD gene. Notably, the p.R370W mutation had no effect on protein localization. In line with the human phenotype, injection of d-lactate into naive mice resulted in hyperuricemia. Thus, hyperuricemia and gout can result from the accumulation of metabolites whose renal excretion is coupled to uric acid reabsorption.
AB - Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid. Although molecular pathways of this underexcretion have been elucidated, its etiology remains mostly unknown. We demonstrate that gout can be caused by a mutation in LDHD within the putative catalytic site of the encoded d-lactate dehydrogenase, resulting in augmented blood levels of d-lactate, a stereoisomer of l-lactate, which is normally present in human blood in miniscule amounts. Consequent excessive renal secretion of d-lactate in exchange for uric acid reabsorption culminated in hyperuricemia and gout. We showed that LDHD expression is enriched in tissues with a high metabolic rate and abundant mitochondria and that d-lactate dehydrogenase resides in the mitochondria of cells overexpressing the human LDHD gene. Notably, the p.R370W mutation had no effect on protein localization. In line with the human phenotype, injection of d-lactate into naive mice resulted in hyperuricemia. Thus, hyperuricemia and gout can result from the accumulation of metabolites whose renal excretion is coupled to uric acid reabsorption.
UR - http://www.scopus.com/inward/record.url?scp=85075718215&partnerID=8YFLogxK
U2 - 10.1172/JCI129057
DO - 10.1172/JCI129057
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31638601
AN - SCOPUS:85075718215
SN - 0021-9738
VL - 129
SP - 5163
EP - 5168
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 12
ER -